# GENGLYCOS (pariglasgene brecaparvovec-opnr) by Ultragenyx Pharmaceutical Inc.: new human prescription drug listing

**Launch Signal Score:** 70/100

| Field | Value |
|---|---|
| Product | GENGLYCOS |
| Generic name | pariglasgene brecaparvovec-opnr |
| NDC | 69794-339 |
| Labeler | Ultragenyx Pharmaceutical Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Approval pathway | BLA |
| Application number | BLA125858 |
| Dosage form | KIT |
| Marketing start | 2026-09-17 |
| Package configurations | 1 |

## Why this score
- Prescription or biologic product.
- Brand or biologic launch.

Source: U.S. FDA National Drug Code (NDC) Directory via openFDA (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=69794-339). Last refreshed: 2026-11-03T18:09:00.764Z.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.